Compass Therapeutics Inc. (CMPX), a clinical-stage, oncology-focused biopharmaceutical company, has a clinical trial catalyst related to its lead drug candidate Tovecimig in patients with advanced biliary tract cancer, to watch this quarter.
Tovecimig is designed to simultaneously block Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to tumor blood vessel formation.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com